Liver biopsy remains the gold standard for the histological assessment of the liver. With clear disadvantages and the rise in the incidences of liver disease, the role of neoadjuvant chemotherapy in colorectal liver metastasis (CRLM) and an explosion of surgical management options available, non-invasive serological and imaging markers of liver histopathology have never been more pertinent in order to assess liver health and stratify patients considered for surgical intervention. Liver MRI is a leading modality in the assessment of hepatic malignancy. Recent technological advancements in multiparametric MRI software such as the LiverMultiScanTMoffers an attractive non-invasive assay of anatomy and histopathology in the pre-operative setting, especially in the context of CRLM. This narrative review examines the evidence for the LiverMultiScanTMin the assessment of hepatic fibrosis, steatosis/steatohepatitis, and potential applications for chemotherapy-associated hepatic changes. We postulate its future role and the hurdles it must surpass in order to be implemented in the pre-operative management of patients undergoing hepatic resection for colorectal liver metastasis. Such a role likely extends to other hepatic malignancies planned for resection.
肝活检仍是肝脏组织学评估的金标准。鉴于其明显缺陷及肝病发病率上升，新辅助化疗在结直肠肝转移中的作用日益凸显，加之手术管理方案激增，非侵入性血清学和影像学标志物在评估肝脏健康及对拟行手术干预患者进行分层方面的重要性前所未有。肝脏磁共振成像在评估肝脏恶性肿瘤方面处于领先地位。多参数磁共振成像软件（如LiverMultiScanTM）的最新技术进展，为术前解剖学和组织病理学评估提供了一种极具吸引力的非侵入性检测手段，尤其在结直肠肝转移的诊疗背景下。本文综述探讨了LiverMultiScanTM在评估肝纤维化、脂肪变性/脂肪性肝炎方面的证据，及其在化疗相关肝脏改变中的潜在应用。我们推测其未来作用及在结直肠肝转移肝切除患者术前管理中需克服的障碍，此类作用很可能延伸至其他计划切除的肝脏恶性肿瘤。
肿瘤(癌症)患者之家